Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats
Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats
复制标题
DOI：
10.1016/j.bbr.2013.07.021
复制
发表时间：
2013-09
影响因子：
2.7
通讯作者：
Ying Wang;Ting Chang;Yun-chun Chen;Rui-guo Zhang;Hua-ning Wang;Wen-jun Wu;Zheng-wu Peng;Q. Tan
中科院分区：
文献类型：
--
作者：
Ying Wang;Ting Chang;Yun-chun Chen;Rui-guo Zhang;Hua-ning Wang;Wen-jun Wu;Zheng-wu Peng;Q. Tan
非典型抗精神病药奎替鲁胺可能对难治性抑郁症（TRD）的增强治疗有效，但证据有限，其潜在机制仍知之甚少。因此，本研究旨在探讨奎替鲁胺是否以及如何作为氟西汀治疗难治性抑郁症大鼠慢性不可预测的轻度应激（CHMS）诱导的增强剂。本研究通过行为学测试和海马神经发生来评估抗抑郁药和抗抑郁药治疗的效果。大约20-30%的抑郁大鼠对氟西汀治疗反应不佳。在他们的海马中，还观察到神经发生的显著减少。而奎替麦加用治疗可显著改善氟西汀治疗难治性抑郁大鼠的抑郁行为，增加海马新生神经元数量。因此，我们的研究结果表明，奎替鲁胺可用作增强剂，在治疗难治性抑郁症部分介导的增加海马中的新生神经元的数量。
Quetiapine, an atypical antipsychotic, may have efficacy as augmentation therapy in treatment resistant depression (TRD), but evidence is limited and the underlying mechanism remains poorly understood. Therefore, this study was aimed to investigate whether and how quetiapine can be served as an augmentation agent in fluoxetine treatment resistant depressive rats induced by chronic unpredictable mild stress (CUMS). In this study, the effects of CUMS regimen and antidepressant treatment were assessed by behavioral tests and hippocampal neurogenesis. Approximately 20–30% of depressive rats respond poorly to fluoxetine treatment. In their hippocampus, a significant decrease of neurogenesis was also observed. However, quetiapine add-on therapy significantly improved the depressive behaviors and increased the number of the newborn neurons in the hippocampus of fluoxetine treatment resistant depressive rats. Thus, our results suggest that quetiapine may be used as an augmentation agent in the treatment resistant depression partly mediated by increasing the number of newborn neurons in the hippocampus.